Skip to content
10-K

Annual Report

Immuneering Corporation IMRX

0001790340-26-000042

← back to feed
Filed
Mar 6, 2026 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Diluted FY 2025 · Dec 31, 2025 44.01M sh
Shares Diluted FY 2025 · Dec 31, 2024 29.98M sh
Capex FY 2025 · Dec 31, 2025 $142.23K
Capex FY 2025 · Dec 31, 2024 $84.88K
Operating Cash Flow FY 2025 · Dec 31, 2025 −$45.34M
Operating Cash Flow FY 2025 · Dec 31, 2024 −$55M
Cash And Equivalents FY 2025 · Dec 31, 2025 $128.65M
Cash And Equivalents FY 2025 · Dec 31, 2024 $36.14M
Stockholders Equity FY 2025 · Dec 31, 2025 $218.48M
Stockholders Equity FY 2025 · Dec 31, 2024 $41.39M
Stockholders Equity FY 2025 · Dec 31, 2023 $90.58M
Current Liabilities FY 2025 · Dec 31, 2025 $10.07M
Current Liabilities FY 2025 · Dec 31, 2024 $7.5M
Total Liabilities FY 2025 · Dec 31, 2025 $13.5M
Total Liabilities FY 2025 · Dec 31, 2024 $11.33M
Current Assets FY 2025 · Dec 31, 2025 $176.25M
Current Assets FY 2025 · Dec 31, 2024 $39.59M
Total Assets FY 2025 · Dec 31, 2025 $231.99M
Total Assets FY 2025 · Dec 31, 2024 $52.71M
Eps Diluted FY 2025 · Dec 31, 2025 −$1.27
Eps Diluted FY 2025 · Dec 31, 2024 −$2.04
Eps Basic FY 2025 · Dec 31, 2025 −$1.27
Eps Basic FY 2025 · Dec 31, 2024 −$2.04
Sga Expense FY 2025 · Dec 31, 2025 $17.3M
Sga Expense FY 2025 · Dec 31, 2024 $16.08M
Rd Expense FY 2025 · Dec 31, 2025 $42.05M
Rd Expense FY 2025 · Dec 31, 2024 $47.96M
Net Income FY 2025 · Dec 31, 2025 −$56.02M
Net Income FY 2025 · Dec 31, 2024 −$61.04M
Operating Income FY 2025 · Dec 31, 2025 −$59.38M
Operating Income FY 2025 · Dec 31, 2024 −$64.07M